Gaurav Bharadwaj1, Viet Nhan1,2, ShanChao Yang1, Xiaocen Li1, Anand Narayanan1, Ana Carolina Macarenco1,3, Yu Shi1,4, Darrion Yang1, Letícia Salvador Vieira1,3, Wenwu Xiao1, Yuanpei Li1, Kit S Lam1. 1. Department of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA. 2. Biology Department, California State University Channel Islands, Camarillo, CA 93012, USA. 3. School of Pharmaceutical Science of Ribeirão Preto, University of Sao Paulo, Ribeirão Preto 14040-903, Brazil. 4. Tianjin Institutes of Pharmaceutical Research Co., Ltd, Tianjin 300193, PR China.
Abstract
AIM: To structurally modify our existing cholic acid (CA)-based telodendrimer (TD; PEG5K-CA8) for effective micellar nanoencapsulation and delivery of the US FDA-approved members of taxane family. MATERIALS & METHODS: Generation of hybrid TDs was achieved by replacing four of the eight CAs with biocompatible organic moieties using solution-phase peptide synthesis. Drug loading was done using the standard evaporation method. RESULTS: Hybrid TDs can generate micelles with narrow size distributions, low critical micelle concentration values (1-6 μM), better hematocompatibility and lack of in vitro cytotoxicity. CONCLUSION: Along with PEG5K-CA8, CA-based hybrid nanoplatform is the first of its kind that can stably encapsulate all three FDA-approved taxanes with nearly 100% efficiency up to 20% (w/w) loading.
AIM: To structurally modify our existing cholic acid (CA)-based telodendrimer (TD; PEG5K-CA8) for effective micellar nanoencapsulation and delivery of the US FDA-approved members of taxane family. MATERIALS & METHODS: Generation of hybrid TDs was achieved by replacing four of the eight CAs with biocompatible organic moieties using solution-phase peptide synthesis. Drug loading was done using the standard evaporation method. RESULTS: Hybrid TDs can generate micelles with narrow size distributions, low critical micelle concentration values (1-6 μM), better hematocompatibility and lack of in vitro cytotoxicity. CONCLUSION: Along with PEG5K-CA8, CA-based hybrid nanoplatform is the first of its kind that can stably encapsulate all three FDA-approved taxanes with nearly 100% efficiency up to 20% (w/w) loading.
Authors: Nicholas J Kenyon; Jennifer M Bratt; Joyce Lee; Juntao Luo; Lisa M Franzi; Amir A Zeki; Kit S Lam Journal: PLoS One Date: 2013-10-25 Impact factor: 3.240